Induction of a Mitogen-Responsive Gene after Expression of the Ha-<i>ras</i>Oncogene in NIH 3T3 Fibroblasts

Werenskiold, A. K.; Hoffmann, Sylvia; Klemenz, Roman

doi:10.1128/mcb.9.11.5207-5214.1989

Cited by 21 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В 1989 г. двумя независимыми лабораториями был открыт белок подавления онкогенности (ST2) [8,9]. Из определения «подавление онкогенеза» вытекает гипотеза, что этот белок способен тормозить неконтролируемую клеточную пролиферацию.…”

Section: патофизиологияunclassified

Soluble tumorigenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome

Fetisova

Намитоков

Гилевич

et al. 2023

jour

View full text Add to dashboard Cite

Many prognostic tools have been developed over the past decades, however, the identification of biomarkers that can predict the risk of acute coronary disease and its associated complications, especially heart failure, remains a promising direction, the study of which will provide understanding of the pathophysiology of this disease and identify new targets for therapy. One such potential biomarker is soluble suppression of tumorigenicity 2, which is able not only to predict left ventricular remodeling and poor clinical outcome among patients with acute coronary syndrome, but also to complement other well-established cardiac biomarkers such as natriuretic peptides and cardiac troponins. At the same time, if a number of separate but often converging pathways are involved in the pathogenesis of acute coronary disease, then multimarker approaches with various combinations of new cardiac biomarkers and their continuous assessment are likely to improve the prediction of cardiac risk and long-term outcomes.

show abstract

Section: патофизиологияunclassified

Soluble tumorigenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome

Fetisova

Намитоков

Гилевич

et al. 2023

jour

View full text Add to dashboard Cite

show abstract

“…I thank also numerous other colleagues including S. Dold, H. Wickham, J.J. Allaire, Y. Xie, the anonymous reviewers and the many contributors at Github and Stackoverflow. Dedicated to Anne Katrin Werenskiold, a former GSF/HMGU employee 49 , who "described a 2.7 kb transcript encoding a ~ 37 kD unglycosylated secreted protein … which in hindsight represented the soluble form sST2" 50 .…”

Section: Acknowledgementsmentioning

confidence: 99%

Exome variants associated with asthma and allergy

Wjst

2022

Sci Rep

View full text Add to dashboard Cite

The mutational spectrum of asthma and allergy associated genes is not known although recent biobank based exome sequencing studies included these traits. We therefore conducted a secondary analysis of exome data from 281,104 UK Biobank samples for association of mostly rare variants with asthma, allergic rhinitis and atopic dermatitis. Variants of interest (VOI) were tabulated, shared genes annotated and compared to earlier genome-wide SNP association studies (GWAS), whole genome sequencing, exome and bisulfit sequencing studies. 354 VOI were significantly associated with asthma, allergic rhinitis and atopic dermatitis. They cluster mainly in two large regions on chromosome 6 and 17. After exclusion of the variants associated with atopic dermatitis and redundant variants, 321 unique VOI remain in 122 unique genes. 30 genes are shared among the 87 genes with increased and the 65 genes with decreased risk for allergic disease. 85% of genes identified earlier by common GWAS SNPs are not replicated here. Most identified genes are located in interferon ɣ and IL33 signaling pathway. These genes include already known but also new pharmacological targets, including the IL33 receptor ST2/IL1RL1, as well as TLR1, ALOX15, GSDMA, BTNL2, IL13 and IKZF3. Future pharmacological studies will need to included these VOI for stratification of the study population paving the way to individualized treatment.

show abstract

“…Growth stimulation expressed gene 2 (ST2) protein is a member of the interleukin 1 receptor/Toll-like receptor superfamily with two forms, i.e., soluble ST2 (sST2) and trans -model ST2 (ST2L). ST2 was previously considered as a key protein affecting cell proliferation and has an impact on tumor development ( Werenskiold et al, 1989 ). ST2L can be expressed in a variety of cells, such as mast cells, macrophages and some lymphocytes (NK cells and Th2 cells, etc.)…”

Section: Introductionmentioning

confidence: 99%

IL-33 and Soluble ST2 Are Associated With Recurrent Spontaneous Abortion in Early Pregnancy

Zhao

Fu²,

Ding³

et al. 2022

Front. Physiol.

View full text Add to dashboard Cite

Normal pregnancy is related to the successful transition from type 1 cellular immunity to type 2 cellular immunity. Therefore, this study aimed to investigate whether there is abnormal expression of cytokines in the process of inducing Recurrent spontaneous abortion (RSA). Interleukin (IL)-33 is a new member of the IL-1 family, and ST2, as IL-33’s receptor, induced the production of type 2 cytokines. In this study, blood samples were collected from 19 non-pregnant women of normal childbearing age, 28 normal pregnant women, and 33 women with RSA. The serum concentrations of IL-33 and ST2 were detected by flow cytometry. Our results showed that the serum concentrations of IL-33 and ST2 in the RSA group were significantly higher than those in the healthy control group (IL-33: P < 0.05; ST2: P < 0.0001), and IL-33 and ST2 had a higher level in the process of RSA predictive value. In addition, this study initially found that the serum concentrations of IL-33 and ST2 were not significantly correlated with the number of weeks of pregnancy, and there was a lower correlation between IL-33 and ST2 during RSA. This result may be related to the small number of cases. This study is the first time to correlate the changes in serum concentrations of IL-33 and ST2 with RSA, which may be a novel biomarker for the prediction and treatment of RSA.

show abstract

Induction of a Mitogen-Responsive Gene after Expression of the Ha-rasOncogene in NIH 3T3 Fibroblasts

Cited by 21 publications

References 38 publications

Soluble tumorigenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome

Soluble tumorigenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome

Exome variants associated with asthma and allergy

IL-33 and Soluble ST2 Are Associated With Recurrent Spontaneous Abortion in Early Pregnancy

Contact Info

Product

Resources

About